Clinical trials: Sarcoidosis,
Sarcoidosis; Antimycobacterial Therapy
Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis
The primary purpose of this study is to investigate the efficacy and safety of oral antimycobacterial therapy in patients with confirmed progressive pulmonary sarcoidosis.
- Trial name
- NCT02024555
- Testing
- Levofloxacin, Ethambutol, Azithromycin
- Where
- 6 sites in United States
- Volunteers
- 97 people
- Sponsor
- Vanderbilt University
Sarcoidosis
Safety Study of Abatacept to Treat Refractory Sarcoidosis
The purpose of this study is to determine how safe and effective Abatacept is in treating patients who have progressive pulmonary sarcoidosis.
- Trial name
- STAR (NCT00739960)
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Lung Diseases, Obstructive, Sarcoidosis
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
The purpose of this study is to evaluate the safety, effectiveness, and side effects of the CryoSpray AblationTM System (CryoSpray AblationTM, "CSA" or "cryospray therapy") to treat benign airway disease in the lung using liquid…
- Conditions
- Lung Diseases, Obstructive, Sarcoidosis, Wegener's Granulomatosis, Rhinoscleroma
- Trial name
- ICEtheBAD (NCT00747461)
- Testing
- CryoSpray Ablation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- CSA Medical, Inc.
Sarcoidosis
Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes
The study hypothesizes that inhibition of the receptor CCR5 by maraviroc will diminish inflammation in patients with sarcoidosis.
- Trial name
- GRADS (NCT02134717)
- Testing
- all subjects will receive maraviroc 300mg orally twice a day for 6 weeks, Bronchoscopy with bronchoalveolar lavage, venipunctures
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Kevin F. Gibson
Cardiac Sarcoidosis
Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis
Sarcoidosis is a heterogeneous disorder of unknown etiology whose signature lesions are granulomatous inflammatory infiltrates in involved tissues. Tissue commonly affected are lungs, skin, eyes, lymph nodes and the heart.
- Trial name
- MAGiC-ART (NCT04017936)
- Testing
- Anakinra
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Virginia Commonwealth University
Sarcoidosis, Pulmonary
Atorvastatin to Treat Pulmonary Sarcoidosis
This study will determine if atorvastatin (Lipitor) can help patients with pulmonary (lung) sarcoidosis and replace or reduce the need for patients to take steroids, such as prednisone.
- Trial name
- NCT00279708
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Ocular Sarcoidosis, Panuveitis
Ocular Sarcoidosis Open Label Trial of ACTHAR Gel
Treatment with ACTHAR Gel will result in a reduction of ocular inflammation in patients with active ocular sarcoidosis that requires systemic immunosuppressant therapy (hypothesis)
- Conditions
- Ocular Sarcoidosis, Panuveitis, Anterior Uveitis
- Trial name
- NCT02725177
- Testing
- Repository Corticotropin Injection, Repository Corticotropin Injection -Treatment Extension
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Cleveland Clinic
Sarcoidosis, Pulmonary
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).
- Trial name
- RESOLVE-Lung (NCT05314517)
- Testing
- Namilumab
- Where
- 47 sites in United States, Belgium and 5 more
- Volunteers
- 107 people
- Sponsor
- Kinevant Sciences GmbH
Sarcoidosis, Pulmonary, Sarcoidosis Lung
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
This is a pilot study to determine whether further research is warranted to assess whether tofacitinib is an effective steroid sparing treatment for pulmonary sarcoidosis.
- Conditions
- Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
- Trial name
- NCT03793439
- Testing
- Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Oregon Health and Science University
Sarcoidosis
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
This study tests the safety and effectiveness of ustekinumab or golimumab compared to placebo (placebo looks like the drugs being studied, but has no active ingredients).
- Trial name
- NCT00955279
- Testing
- Golimumab, Ustekinumab
- Where
- 53 sites in United States, Belgium and 7 more
- Volunteers
- 173 people
- Sponsor
- Centocor, Inc.
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Noninfectious Uveitis
This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
- Trial name
- NCT00685399
- Testing
- AIN457, AIN 457
- Where
- 23 sites in United States, Germany
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Hepatic Sarcoidosis, Elevated Alkaline Phosphatase
Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis
This study aims to (1) evaluate efficacy of UDCA in improving liver function and quality of life; (2) monitor safety, tolerability of UDCA, as well as progression of hepatic sarcoidosis and liver disease, in patients diagnosed…
- Trial name
- NCT03602976
- Testing
- Ursodeoxycholic Acid
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Ethan Weinberg
Sarcoidosis
Trial of Antimycobacterial Therapy in Sarcoidosis
Growing research from independent laboratories provide an association between mycobacteria and sarcoidosis. More recent immunologic and molecular studies demonstrate immune responses to mycobacteria virulence factors.
- Trial name
- CLEAR (NCT01074554)
- Testing
- Antibiotic Regimen
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt University
Neuropathy of Sarcoidosis
Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
The purpose of this study is to determine whether ARA 290, a new class of compound, is effective in the treatment of the neuropathic symptoms of sarcoidosis.
- Trial name
- NCT02039687
- Testing
- ARA 290
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 64 people
- Sponsor
- Araim Pharmaceuticals, Inc.
Sarcoidosis, Fatigue
SPARC Smartphone Application for the Management of Sarcoidosis-Associated Fatigue
Fatigue is a pervasive and disabling symptom in sarcoidosis with limited treatment options. There is a significant association between heightened stress and sarcoidosis-associated fatigue.
- Trial name
- SPARC (NCT05230693)
- Testing
- Sarcoidosis Patient Assessment and Resource Companion App, Enhanced Standard Care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Medical University of South Carolina
Pulmonary Sarcoidosis
Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
The purpose of this study is to assess if ACZ885 will improve lung function in association with reduction of tissue inflammation in patients with chronic sarcoidosis.
- Trial name
- NCT02888080
- Testing
- ACZ885
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Sarcoidosis
Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK), and preliminary efficacy of multiple ascending doses of IV efzofitimod…
- Trial name
- NCT03824392
- Where
- 15 sites in United States
- Volunteers
- 37 people
- Sponsor
- aTyr Pharma, Inc.
Sarcoidosis-associated Pulmonary Hypertension
A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag
Oral selexipag is commercially available in several countries for the treatment of a particular group of pulmonary hypertension (PH) called pulmonary arterial hypertension (PAH).
- Trial name
- SPHINX (NCT03942211)
- Testing
- Selexipag
- Where
- 38 sites in United States, Belgium and 8 more
- Volunteers
- 10 people
- Sponsor
- Actelion
Sarcoidosis
Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis
Sarcoidosis is a disease believed to be due to immune cells, cells which normally protect the body, but are now attacking lungs, heart, nerves, or other organs or systems within the body.
- Trial name
- NCT00282438
- Testing
- Autologous hematopoietic stem cell transplantation, Allogeneic stem cell transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Northwestern University
Sarcoidosis
Trial of Adalimumab in Progressive Sarcoidosis
Sarcoidosis is a rare disease that can affect any organ in the body. It is characterized by the buildup of immune-system (fights off infection in the body) cells in organs.
- Trial name
- NCT00311246
- Testing
- Adalimumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Chicago